Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Determination of HIV-1 co-receptor usage.

Cavarelli M, Scarlatti G.

Methods Mol Biol. 2014;1087:197-206. doi: 10.1007/978-1-62703-670-2_16.

PMID:
24158824
2.

Determination of co-receptor usage of HIV-1.

Schuitemaker H, Kootstra NA.

Methods Mol Biol. 2005;304:327-32.

PMID:
16061986
3.

gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors.

Catani MV, Corasaniti MT, Navarra M, Nisticò G, Finazzi-Agrò A, Melino G.

J Neurochem. 2000 Jun;74(6):2373-9.

4.

Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.

Sabri F, Tresoldi E, Di Stefano M, Polo S, Monaco MC, Verani A, Fiore JR, Lusso P, Major E, Chiodi F, Scarlatti G.

Virology. 1999 Nov 25;264(2):370-84.

6.

Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.

Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, Martinez-A C, O'Brien SJ, Dean M, Collman RG, Doms RW.

J Virol. 1998 Sep;72(9):7450-8.

8.

The puzzling role of CXCR4 in human immunodeficiency virus infection.

Vicenzi E, Liò P, Poli G.

Theranostics. 2013;3(1):18-25. doi: 10.7150/thno.5392. Epub 2013 Jan 13. Review.

9.

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Scarlatti G, Tresoldi E, Björndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyö EM, Lusso P.

Nat Med. 1997 Nov;3(11):1259-65.

PMID:
9359702
10.
11.

Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.

Dubey S, Khalid M, Wesley C, Khan SA, Wanchu A, Jameel S.

J Clin Virol. 2008 Sep;43(1):25-31. doi: 10.1016/j.jcv.2008.03.026. Epub 2008 May 6.

PMID:
18462992
12.
13.

Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.

Ghezzi S, Menzo S, Brambilla A, Bordignon PP, Lorini AL, Clementi M, Poli G, Vicenzi E.

Virology. 2001 Feb 15;280(2):253-61.

14.

CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses.

Borsetti A, Parolin C, Ridolfi B, Sernicola L, Geraci A, Ensoli B, Titti F.

J Virol. 2000 Jul;74(14):6689-94.

15.

Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Björndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyö EM.

J Virol. 1997 Oct;71(10):7478-87.

16.

Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient?

Lathey JL, Brambilla D, Goodenow MM, Nokta M, Rasheed S, Siwak EB, Bremer JW, Huang DD, Yi Y, Reichelderfer PS, Collman RG.

J Leukoc Biol. 2000 Sep;68(3):324-30.

PMID:
10985247
17.

HIV coreceptor usage and drug treatment.

Regoes R, Bonhoeffer S.

J Theor Biol. 2002 Aug 21;217(4):443-57.

PMID:
12234752
19.

The HIV-1 Tat protein selectively enhances CXCR4 and inhibits CCR5 expression in megakaryocytic K562 cells.

Mondal D, Williams CA, Ali M, Eilers M, Agrawal KC.

Exp Biol Med (Maywood). 2005 Oct;230(9):631-44.

PMID:
16179731
20.

Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5.

Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, Wang JM, Puri A, Blumenthal R.

J Virol. 2000 Jul;74(14):6377-85.

Supplemental Content

Support Center